CHECKMATE 040: EFFICACY, HEPATIC SAFETY, AND BIOMARKERS OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Sangro, Bruno [1 ,2 ]
Hsu, Chiun [3 ]
Kang, Yoon-Koo [4 ]
Kim, Tae-You [5 ]
El-Khoueiry, Anthony [6 ]
Santoro, Armando [7 ]
Melero, Ignacio [8 ]
Kudo, Masatoshi [9 ]
Hou, Ming-Mo [10 ]
Pena, Ana Matilla [11 ]
Tovoli, Francesco [12 ]
Knox, Jennifer J. [13 ]
He, Aiwu Ruth [14 ]
El-Rayes, Bassel [15 ]
Acosta, Mirelis Rivera [16 ]
Lim, Ho-Yeong [17 ]
Neely, Jaclyn [18 ]
Zhao, Huanyu [18 ]
Anderson, Jeffrey [18 ]
Yau, Thomas [19 ]
机构：
[1] Clin Univ Navarra, Idisna, Pamplona, Spain
[2] Ciberehd, Madrid, Spain
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Univ Ulsan, Asan Med Ctr, Ulsan, South Korea
[5] Seoul Natl Univ, Seoul, South Korea
[6] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] Humanitas Univ, Humanitas Clin & Res Ctr, Rozzano, Italy
[8] Univ Navarra, Pamplona, Spain
[9] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Higashiosaka, Osaka, Japan
[10] Chang Gung Mem Hosp, Taipei, Taiwan
[11] Hosp Gen Univ Gregorio Maranon, Serv Digest, Madrid, Spain
[12] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[13] Princess Margaret Canc Ctr, Toronto, ON, Canada
[14] Georgetown Univ Hosp, Washington, DC 20007 USA
[15] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[16] Fdn Invest, San Juan, PR USA
[17] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[18] Bristol Myers Squibb, New York, NY USA
[19] Univ Hong Kong, Hong Kong, Peoples R China
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
200
引用
下载
收藏
页码：131A / 132A
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of nivolumab plus ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study
    Yau, T.
    Hsu, C.
    Kang, Y.
    Kim, T.
    Hou, M.
    Lim, H.
    Chao, Y.
    Kim, Y.
    Ikeda, M.
    Choo, S.
    Neely, J.
    Shen, Y.
    Tschaika, M.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S233 - S233
  • [2] Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040
    Sangro, Bruno
    He, Aiwu Ruth
    Yau, Thomas
    Hsu, Chiun
    Kang, Yoon-Koo
    Kim, Tae-You
    Santoro, Armando
    Melero, Ignacio
    Kudo, Masatoshi
    Ho, Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer
    El-Rayes, Bassel
    Acosta, Mirelis Rivera
    Neely, Jaclyn
    Shen, Yun
    Tschaika, Marina
    El-Khoureiry, Anthony
    JOURNAL OF HEPATOLOGY, 2020, 73 : S121 - S122
  • [3] Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
    Sangro, Bruno
    Yau, Thomas
    El-Khoueiry, Anthony B.
    Kudo, Masatoshi
    Shen, Yun
    Tschaika, Marina
    Roy, Amit
    Feng, Yan
    Gao, Ling
    Aras, Urvi
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (08): : 1445 - 1457
  • [4] Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
    Yau, Thomas
    Kang, Yoon-Koo
    Kim, Tae-You
    El-Khoueiry, Anthony B.
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Lim, Ho-Yeong
    Neely, Jaclyn
    Shen, Yun
    Wisniewski, Tami
    Anderson, Jeffrey
    Hsu, Chiun
    JAMA ONCOLOGY, 2020, 6 (11)
  • [5] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040
    He, Aiwu Ruth
    Yau, Thomas
    Hsu, Chiun
    Kang, Yoon-Koo
    Kim, Tae-You
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Neely, Jaclyn
    Shen, Yun
    Tschaika, Marina
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
    Yau, Thomas
    Kang, Yoon-Koo
    Kim, Tae-You
    El-Khoueiry, Anthony B.
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Neely, Jaclyn
    Shen, Yun
    Baccan, Carlos
    Dela Cruz, Christine Marie
    Hsu, Chiun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Nivolumab (NIVO) plus ipilimumab (IPI) plus cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040
    Yau, Thomas
    Zagonel, Vittorina
    Santoro, Armando
    Acosta-Rivera, Mirelis
    Choo, Su Pin
    Matilla, Ana
    He, Aiwu Ruth
    Gracian, Antonio Cubillo
    El-Khoueiry, Anthony B.
    Sangro, Bruno
    Eldawy, Tarek
    Bruix, Jordi
    Frassineti, Giovanni
    Vaccaro, Gina M.
    Tschaika, Marina
    Scheffold, Christian
    Shen, Yun
    Neely, Jaclyn
    Piscaglia, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
    Melero, I.
    Yau, T.
    Kang, Y. -K.
    Kim, T. -Y.
    Santoro, A.
    Sangro, B.
    Kudo, M.
    Hou, M. -M.
    Matilla, A.
    Tovoli, F.
    Knox, J.
    He, A. R.
    El-Rayes, B.
    Acosta-Rivera, M.
    Lim, H. Y.
    Soleymani, S.
    Yao, J.
    Neely, J.
    Tschaika, M.
    Hsu, C.
    El-Khoueiry, A. B.
    ANNALS OF ONCOLOGY, 2024, 35 (06) : 537 - 548
  • [9] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040
    Melero, I.
    Yau, T.
    Kang, Y.
    Kim, T.
    Santoro, A.
    Sangro, B.
    Kudo, M.
    Hou, M.
    Matilla, A.
    Tovoli, F.
    Knox, J.
    He, A.
    El-Rayes, B.
    Acosta-Rivera, M.
    Lim, H.
    Soleymani, S.
    Yao, J.
    Neely, J.
    Tschaika, M.
    Hsu, C.
    El-Khoueiry, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S361 - S361
  • [10] Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study
    Choo, S. P.
    Yau, T.
    Hsu, C.
    Kang, Y-K.
    Hou, M-M.
    Yeo, W.
    Numata, K.
    Chopra, A.
    Baakili, A.
    Dela Cruz, C.
    Zhao, H.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345